PDL1 positive NK cell cancer therapy
Provided herein are methods of treating cancer in a subject comprising detecting the amount of PD-L1 (+) natural killer (NK) cells in a biological sample from the subject, and treating the subject with an anti-cancer therapy. Provided herein are methods of treating cancer in a patient comprising iso...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | Chinese English |
Published |
11.03.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Provided herein are methods of treating cancer in a subject comprising detecting the amount of PD-L1 (+) natural killer (NK) cells in a biological sample from the subject, and treating the subject with an anti-cancer therapy. Provided herein are methods of treating cancer in a patient comprising isolating natural killer (NK) cells from a subject, generating a population of PD-L1 (+) NK cells from the isolated NK cells, and administering the population of PD-L1 (+) NK cells to the patient.
本文提供了治疗受试者的癌症的方法,所述方法包括检测来自所述受试者的生物样本中PD-L1(+)自然杀伤(NK)细胞的量,以及用抗癌疗法治疗所述受试者。本文提供了治疗患者的癌症的方法,所述方法包括从受试者中分离出自然杀伤(NK)细胞,从所述分离的NK细胞中产生PD-L1(+)NK细胞群,以及将所述PD-L1(+)NK细胞群施用给所述患者。 |
---|---|
AbstractList | Provided herein are methods of treating cancer in a subject comprising detecting the amount of PD-L1 (+) natural killer (NK) cells in a biological sample from the subject, and treating the subject with an anti-cancer therapy. Provided herein are methods of treating cancer in a patient comprising isolating natural killer (NK) cells from a subject, generating a population of PD-L1 (+) NK cells from the isolated NK cells, and administering the population of PD-L1 (+) NK cells to the patient.
本文提供了治疗受试者的癌症的方法,所述方法包括检测来自所述受试者的生物样本中PD-L1(+)自然杀伤(NK)细胞的量,以及用抗癌疗法治疗所述受试者。本文提供了治疗患者的癌症的方法,所述方法包括从受试者中分离出自然杀伤(NK)细胞,从所述分离的NK细胞中产生PD-L1(+)NK细胞群,以及将所述PD-L1(+)NK细胞群施用给所述患者。 |
Author | DONG WENJUAN YU JIANHUA CALIGIURI MICHAEL A |
Author_xml | – fullname: YU JIANHUA – fullname: DONG WENJUAN – fullname: CALIGIURI MICHAEL A |
BookMark | eNrjYmDJy89L5WRQCXDxMVQoyC_OLMksS1Xw81ZITs3JUUhOzEtOLVIoyUgtSiyo5GFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8c5-hoYmhubG5pYmjsbEqAEAgaYnmQ |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | PDL1阳性NK细胞癌症治疗 |
ExternalDocumentID | CN114173794A |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_CN114173794A3 |
IEDL.DBID | EVB |
IngestDate | Fri Aug 30 05:41:00 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | Chinese English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_CN114173794A3 |
Notes | Application Number: CN202080046676 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220311&DB=EPODOC&CC=CN&NR=114173794A |
ParticipantIDs | epo_espacenet_CN114173794A |
PublicationCentury | 2000 |
PublicationDate | 20220311 |
PublicationDateYYYYMMDD | 2022-03-11 |
PublicationDate_xml | – month: 03 year: 2022 text: 20220311 day: 11 |
PublicationDecade | 2020 |
PublicationYear | 2022 |
RelatedCompanies | WEIGHTING CITY |
RelatedCompanies_xml | – name: WEIGHTING CITY |
Score | 3.5180101 |
Snippet | Provided herein are methods of treating cancer in a subject comprising detecting the amount of PD-L1 (+) natural killer (NK) cells in a biological sample from... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
Title | PDL1 positive NK cell cancer therapy |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220311&DB=EPODOC&locale=&CC=CN&NR=114173794A |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQAZ14aZpilKibkpSSqmtiZG6pm5RibKxrkmxpamGRDLo3Dbzaws_MI9TEK8I0gokhC7YXBnxOaDn4cERgjkoG5vcScHldgBjEcgGvrSzWT8oECuXbu4XYuqhBe8dGRsA0aqjm4mTrGuDv4u-s5uxs6-yn5hdkC2z2G5obAxOfIzMDK6gZDTpn3zXMCbQrpQC5SnETZGALAJqWVyLEwFSVIczA6Qy7eU2YgcMXOuENZELzXrEIg0qAi4-hAmSRVVmqgp-3AmjQXSEZFG1FCpB9VJWiDIpuriHOHrpA6-Lhfot39kO4zFiMgQXY50-VYFAwS01KMbBMTExKMTMzSUy0TExOMTNIMzFLAbb_DVMskyUZpHCbI4VPUpqBCxROoGVUhoYyDCwlRaWpssB6tSRJDhwgALw0ewo |
link.rule.ids | 230,309,786,891,25594,76906 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3LTsMwzBoDMW4wQDBeRZp6q1j6XA8VYumqwrqsQgXtNrVNEXCAaSsg-HqcrGNc4BYlkpM4dvyI7QC0RcVLi-upxjNeaKbuuFrGDUMzc9fqdnPxb5qMtmB2eGfejK1xDZ6XuTCyTuiHLI6IHJUjv5fyvp6unFi-jK2cX2RP2PV6GSSer1bWsa4jjRLV73n9eOSPqEqpR5nKbj1U-4ljIPFdrcG6I6rzCtXpvieyUqa_RUqwDRsxQnspd6D29diEBl3-vNaEzWH14I3Nivfmu9CO_YgoiyCr90JhA0U43ZVcHNtMWeRRfe7BedBPaKjhdJOfvU0oW63M2Ic62vzFASh2kfGOm6YZt20zTd0053bnwbQ56v-Eu_khtP6G0_pv8AwaYTKMJtE1GxzBlsCZCKki5Bjq5eytOEEZW2anEjnfpYp99w |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=PDL1+positive+NK+cell+cancer+therapy&rft.inventor=YU+JIANHUA&rft.inventor=DONG+WENJUAN&rft.inventor=CALIGIURI+MICHAEL+A&rft.date=2022-03-11&rft.externalDBID=A&rft.externalDocID=CN114173794A |